IL245538A0 - Treatment methods for abnormal muscle activity - Google Patents

Treatment methods for abnormal muscle activity

Info

Publication number
IL245538A0
IL245538A0 IL245538A IL24553816A IL245538A0 IL 245538 A0 IL245538 A0 IL 245538A0 IL 245538 A IL245538 A IL 245538A IL 24553816 A IL24553816 A IL 24553816A IL 245538 A0 IL245538 A0 IL 245538A0
Authority
IL
Israel
Prior art keywords
methods
treating abnormal
muscular activity
abnormal muscular
activity
Prior art date
Application number
IL245538A
Other languages
English (en)
Hebrew (he)
Inventor
Pratik Shah
Original Assignee
Pratik Shah
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pratik Shah, Auspex Pharmaceuticals Inc filed Critical Pratik Shah
Publication of IL245538A0 publication Critical patent/IL245538A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
IL245538A 2013-11-22 2016-05-08 Treatment methods for abnormal muscle activity IL245538A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907675P 2013-11-22 2013-11-22
PCT/US2014/066740 WO2015077520A1 (en) 2013-11-22 2014-11-21 Methods of treating abnormal muscular activity

Publications (1)

Publication Number Publication Date
IL245538A0 true IL245538A0 (en) 2016-06-30

Family

ID=53180159

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245538A IL245538A0 (en) 2013-11-22 2016-05-08 Treatment methods for abnormal muscle activity

Country Status (8)

Country Link
US (1) US20160303110A1 (enExample)
EP (1) EP3071565A4 (enExample)
JP (1) JP2017503756A (enExample)
CA (1) CA2930167A1 (enExample)
HK (1) HK1224294A1 (enExample)
IL (1) IL245538A0 (enExample)
MX (1) MX2016006622A (enExample)
WO (1) WO2015077520A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態
AU2014357518A1 (en) 2013-12-03 2016-06-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
EP2918266A1 (en) * 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
PL3265085T3 (pl) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US10786202B2 (en) 2016-09-28 2020-09-29 International Business Machines Corporation Quantifying grip strength and characterizing movement idioms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7367953B2 (en) * 2003-11-26 2008-05-06 Ge Medical Systems Global Technology Company Method and system for determining a period of interest using multiple inputs
BRPI0708071A8 (pt) * 2006-02-17 2017-12-26 Birds Pharma Gmbh Berolina Innovative Res & Development Services Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
ES2525932T3 (es) * 2006-05-02 2015-01-02 The Trustees Of The University Of Pennsylvania Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología
US8008500B2 (en) * 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
EP2674104B1 (en) * 2008-06-12 2015-05-27 Amygdala Pty Ltd Detection of hypokinetic and/or hyperkinetic states
PL2318035T3 (pl) * 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
NZ591615A (en) * 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
US20120003330A1 (en) * 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
US9676810B2 (en) * 2010-07-08 2017-06-13 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
US9901564B2 (en) * 2012-03-23 2018-02-27 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders

Also Published As

Publication number Publication date
MX2016006622A (es) 2016-12-09
HK1224294A1 (zh) 2017-08-18
US20160303110A1 (en) 2016-10-20
CA2930167A1 (en) 2015-05-28
EP3071565A1 (en) 2016-09-28
WO2015077520A1 (en) 2015-05-28
JP2017503756A (ja) 2017-02-02
EP3071565A4 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
ZA201505956B (en) Methods of treating melanoma
LT2948479T (lt) Bradikinino sąlygotų sutrikimų įvertinimas ir gydymas
PL3626270T3 (pl) Leczenie chorób sercowo-naczyniowych
PL3007726T3 (pl) Metody leczenia tauopatii
SG10201703677VA (en) Methods of treating s. aureus-associated diseases
EP3071565A4 (en) Methods of treating abnormal muscular activity
IL239309A0 (en) Methods for the treatment and prevention of respiratory conditions
IL237449A0 (en) Methods for treating health conditions related to hair
GB201308466D0 (en) Improved process for treatment of minewater
GB201403716D0 (en) Catalytic treatment
IL241096A0 (en) Treatment methods
GB201303737D0 (en) Catalytic treatment
ZA201601626B (en) Treatment of gases
PL3041506T3 (pl) Sposób leczenia
GB201316043D0 (en) Cardiac arrest treatment
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201221032D0 (en) Method of treatment